|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Brenner H, Rothenbacher D and Arndt V:
Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477.
2009. View Article : Google Scholar
|
|
3
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar
|
|
4
|
Cunningham D, Starling N, Rao S, et al:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
6
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: a new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hofmann M, Stoss O, Shi D, et al:
Assessment of a HER2 scoring system for gastric cancer: results
from a validation study. Histopathology. 52:797–805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kimelman D and Kirschner M: Synergistic
induction of mesoderm by FGF and TGF-beta and the identification of
an mRNA coding for FGF in the early Xenopus embryo. Cell.
51:869–877. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Moerlooze L, Spencer-Dene B, Revest JM,
Hajihosseini M, Rosewell I and Dickson C: An important role for the
IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in
mesenchymal-epithelial signalling during mouse organogenesis.
Development. 127:483–492. 2000.PubMed/NCBI
|
|
10
|
Turner N and Grose R: Fibroblast growth
factor signalling: from development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kunii K, Davis L, Gorenstein J, et al:
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3
signaling for growth and survival. Cancer Res. 68:2340–2348. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toyokawa T, Yashiro M and Hirakawa K:
Co-expression of keratinocyte growth factor and K-sam is an
independent prognostic factor in gastric carcinoma. Oncol Rep.
21:875–880. 2009.PubMed/NCBI
|
|
13
|
Zhao WM, Wang L, Park H, et al: Monoclonal
antibodies to fibroblast growth factor receptor 2 effectively
inhibit growth of gastric tumor xenografts. Clin Cancer Res.
16:5750–5758. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao G, Li WY, Chen D, et al: A novel,
selective inhibitor of fibroblast growth factor receptors that
shows a potent broad spectrum of antitumor activity in several
tumor xenograft models. Mol Cancer Ther. 10:2200–2210. 2011.
View Article : Google Scholar
|
|
15
|
Brooks AN, Kilgour E and Smith PD:
Molecular pathways: fibroblast growth factor signaling: a new
therapeutic opportunity in cancer. Clin Cancer Res. 18:1855–1862.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shin EY, Lee BH, Yang JH, et al:
Up-regulation and co-expression of fibroblast growth factor
receptors in human gastric cancer. J Cancer Res Clin Oncol.
126:519–528. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oki M, Yamamoto H, Taniguchi H, Adachi Y,
Imai K and Shinomura Y: Overexpression of the receptor tyrosine
kinase EphA4 in human gastric cancers. World J Gastroenterol.
14:5650–5656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye Y, Shi Y, Zhou Y, et al: The fibroblast
growth factor receptor-4 Arg388 allele is associated with gastric
cancer progression. Ann Surg Oncol. 17:3354–3361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye YW, Zhou Y, Yuan L, et al: Fibroblast
growth factor receptor 4 regulates proliferation and antiapoptosis
during gastric cancer progression. Cancer. 117:5304–5313. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eswarakumar VP, Lax I and Schlessinger J:
Cellular signaling by fibroblast growth factor receptors. Cytokine
Growth Factor Rev. 16:139–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vainikka S, Joukov V, Wennström S, Bergman
M, Pelicci PG and Alitalo K: Signal transduction by fibroblast
growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. J Biol
Chem. 269:18320–18326. 1994.PubMed/NCBI
|
|
22
|
Wang JK, Gao G and Goldfarb M: Fibroblast
growth factor receptors have different signaling and mitogenic
potentials. Mol Cell Biol. 14:181–188. 1994.PubMed/NCBI
|
|
23
|
Shaoul E, Reich-Slotky R, Berman B and Ron
D: Fibroblast growth factor receptors display both common and
distinct signaling pathways. Oncogene. 10:1553–1561.
1995.PubMed/NCBI
|
|
24
|
Xian W, Schwertfeger KL and Rosen JM:
Distinct roles of fibroblast growth factor receptor 1 and 2 in
regulating cell survival and epithelial mesenchymal transition. Mol
Endocrinol. 21:987–1000. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Turner N, Pearson A, Sharpe R, et al:
FGFR1 amplification drives endocrine therapy resistance and is a
therapeutic target in breast cancer. Cancer Res. 70:2085–2094.
2010. View Article : Google Scholar
|
|
26
|
Theillet C, Adelaide J, Louason G, et al:
FGFRI and PLAT genes and DNA amplification at 8p12 in breast and
ovarian cancers. Genes Chromosomes Cancer. 7:219–226. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Simon R, Richter J, Wagner U, et al:
High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12
(FGFR1) copy number alterations in urinary bladder cancer. Cancer
Res. 61:4514–4519. 2001.PubMed/NCBI
|
|
28
|
Weiss J, Sos ML, Seidel D, et al: Frequent
and focal FGFR1 amplification associates with therapeutically
tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl
Med. 2:62ra932010.PubMed/NCBI
|
|
29
|
Sato T, Oshima T, Yoshihara K, et al:
Overexpression of the fibroblast growth factor receptor-1 gene
correlates with liver metastasis in colorectal cancer. Oncol Rep.
21:211–216. 2009.PubMed/NCBI
|
|
30
|
Sugiura K, Ozawa S, Kitagawa Y, Ueda M and
Kitajima M: Co-expression of aFGF and FGFR-1 is predictive of a
poor prognosis in patients with esophageal squamous cell carcinoma.
Oncol Rep. 17:557–564. 2007.PubMed/NCBI
|
|
31
|
Bange J, Prechtl D, Cheburkin Y, et al:
Cancer progression and tumor cell motility are associated with the
FGFR4 Arg(388) allele. Cancer Res. 62:840–847. 2002.PubMed/NCBI
|
|
32
|
Thussbas C, Nahrig J, Streit S, et al:
FGFR4 Arg388 allele is associated with resistance to adjuvant
therapy in primary breast cancer. J Clin Oncol. 24:3747–3755. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marmé F, Hielscher T, Hug S, et al:
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele
predicts prolonged survival and platinum sensitivity in advanced
ovarian cancer. Int J Cancer. 131:E586–E591. 2012.PubMed/NCBI
|
|
34
|
Frullanti E, Berking C, Harbeck N, et al:
Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a
cancer prognostic factor. Eur J Cancer Prev. 20:340–347. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leung HY, Gullick WJ and Lemoine NR:
Expression and functional activity of fibroblast growth factors and
their receptors in human pancreatic cancer. Int J Cancer.
59:667–675. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takahashi A, Sasaki H, Kim SJ, et al:
Identification of receptor genes in renal cell carcinoma associated
with angiogenesis by differential hybridization technique. Biochem
Biophys Res Commun. 257:855–859. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hattori Y, Odagiri H, Nakatani H, et al:
K-sam, an amplified gene in stomach cancer, is a member of the
heparin-binding growth factor receptor genes. Proc Natl Acad Sci
USA. 87:5983–5987. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heiskanen M, Kononen J, Bärlund M, et al:
CGH, cDNA and tissue microarray analyses implicate FGFR2
amplification in a small subset of breast tumors. Anal Cell Pathol.
22:229–234. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jang JH, Shin KH and Park JG: Mutations in
fibroblast growth factor receptor 2 and fibroblast growth factor
receptor 3 genes associated with human gastric and colorectal
cancers. Cancer Res. 61:3541–3543. 2001.PubMed/NCBI
|
|
40
|
Davies H, Hunter C, Smith R, et al:
Somatic mutations of the protein kinase gene family in human lung
cancer. Cancer Res. 65:7591–7595. 2005.PubMed/NCBI
|
|
41
|
Byron SA, Gartside MG, Wellens CL, et al:
FGFR2 mutations are rare across histologic subtypes of ovarian
cancer. Gynecol Oncol. 117:125–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pollock PM, Gartside MG, Dejeza LC, et al:
Frequent activating FGFR2 mutations in endometrial carcinomas
parallel germline mutations associated with craniosynostosis and
skeletal dysplasia syndromes. Oncogene. 26:7158–7162. 2007.
View Article : Google Scholar
|
|
43
|
Gartside MG, Chen H, Ibrahimi OA, et al:
Loss-of-function fibroblast growth factor receptor-2 mutations in
melanoma. Mol Cancer Res. 7:41–54. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hattori Y, Itoh H, Uchino S, et al:
Immunohistochemical detection of K-sam protein in stomach cancer.
Clin Cancer Res. 2:1373–1381. 1996.PubMed/NCBI
|
|
45
|
Nord H, Segersten U, Sandgren J, et al:
Focal amplifications are associated with high grade and recurrences
in stage Ta bladder carcinoma. Int J Cancer. 126:1390–1402.
2010.PubMed/NCBI
|
|
46
|
Khnykin D, Troen G, Berner JM and Delabie
A: The expression of fibroblast growth factors and their receptors
in Hodgkin’s lymphoma. J Pathol. 208:431–438. 2006.
|
|
47
|
Rosty C, Aubriot MH, Cappellen D, et al:
Clinical and biological characteristics of cervical neoplasias with
FGFR3 mutation. Mol Cancer. 4:152005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hernández S, de Muga S, Agell L, et al:
FGFR3 mutations in prostate cancer: association with low-grade
tumors. Modern Pathol. 22:848–856. 2009.PubMed/NCBI
|
|
49
|
Goriely A, Hansen RMS, Taylor IB, et al:
Activating mutations in FGFR3 and HRAS reveal a shared genetic
origin for congenital disorders and testicular tumors. Nat Genet.
41:1247–1252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
50
|
van Oers JM, Wild PJ, Burger M, et al:
FGFR3 mutations and a normal CK20 staining pattern define low-grade
noninvasive urothelial bladder tumours. Eur Urol. 52:760–768.
2007.
|
|
51
|
Mhawrech-Fauceglia P, Cheney RT, Fischer
G, Beek A and Herrmann FR: FGFR3 and p53 protein expressions in
patients with pTa and pT1 urothelial bladder cancer. Eur J Surg
Oncol. 32:231–237. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qiu WH, Zhou BS, Chu PGG, et al:
Over-expression of fibroblast growth factor receptor 3 in human
hepatocellular carcinoma. World J Gastroenterol. 11:5266–5272.
2005.PubMed/NCBI
|
|
53
|
Kuroso K, Imai Y, Kobayashi M, et al:
Immunohistochemical detection of fibroblast growth factor receptor
3 in human breast cancer: correlation with
clinicopathological/molecular parameters and prognosis.
Pathobiology. 77:231–240. 2010. View Article : Google Scholar
|
|
54
|
Katoh M and Nakagama H: FGF receptors:
cancer biology and therapeutics. Med Res Rev. 34:280–300. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qiu H, Yashiro M, Zhang X, Miwa A and
Hirakawa K: A FGFR2 inhibitor, Ki23057, enhances the
chemosensitivity of drug-resistant gastric cancer cells. Cancer
Lett. 307:47–52. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xie L, Su X, Zhang L, et al: FGFR2 gene
amplification in gastric cancer predicts sensitivity to the
selective FGFR inhibitor AZD4547. Clin Cancer Res. 19:2572–2583.
2013. View Article : Google Scholar : PubMed/NCBI
|
